🏛️ Verified NIH Record • Updated 2026-08-13
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors (NCT06425926)
🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Georgiamune Inc
🩺 Plain-English Summary (8th-Grade Level)
GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary effect through selective inhibition of regulatory T-cells (Tregs).
Who can join: Review the eligibility criteria below.
Location: HonorHealth Research Institute — Scottsdale, Arizona
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (11 Sites)
- HonorHealth Research Institute — Scottsdale, Arizona
- Comprehensive Blood and Cancer Center — Bakersfield, California
- Providence Medical Foundation — Fullerton, California
- The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate — Los Angeles, California
- UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California
- Massachusetts General Hospital — Boston, Massachusetts
- Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana — Billings, Montana
- Weill Cornell Medicine - New York Presbyterian Hospital — New York, New York
- University of Cincinnati Cancer Center — Cincinnati, Ohio
- Tennessee Oncology, PLLC — Nashville, Tennessee
- Virginia Commonwealth University — Richmond, Virginia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.